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PregnancyAbstract Objectives: Limited dose warfarin (LDW) throughout pregnancy was suggested to pro-
vide safe and effective anticoagulation in pregnant patients with mechanical heart valve prosthesis
(MHVP). Our aim was to study its rate of failure in achieving the INR recommended for high-risk
patients with mitral (±aortic) MHVP.
Methods: A clinical trial was designed to compare failure rates of either LDW (65 mg/day) or
phenindione (6100 mg/day) to achieve target INR (2.5–3.5) in pregnant (Group A) and non-preg-
nant patients with MHVP (Group B). Eligibility criteria: young females (18–40 years), mitral
(±aortic) MHVP, NYHA class I-II and achieving INR during the last three months. At Ain-Shams
University, 100 patients were randomized in each group to either receive LDW or phenindione in a
3:1 ratio. Primary outcome was failure to achieve target INR on two successive controls.
Results: Group A: follow-up was complete, twenty patients on LDW (26.7%; CI at 95%: 16.7–
36.7%) failed to achieve target but none on phenindione (P= 0.003). Group B: follow-up was
97%, four LDW patients failed to achieve target (5.3%; 0.2–10.4%) and none on phenindione
(P= 0.5). Pregnant patients received larger doses of either OA (P< 0.0001), achieved lower
INR (P< 0.0001) and experienced more failures to maintain INR (relative risk: 5; 1.8–13.9;
P= 0.002), compared to controls. We had no patient mortality or fetal embryopathy but 11 fetal
losses that were related to lower INR (P= 0.039).
Conclusions: LDW may be insufﬁcient to achieve the INR target recommended for high-risk preg-
nant patients with mitral (±aortic) MHVP. Phenindione can offer an effective and probably safe
alternative (NCT01758640).
ª 2014 Production and hosting by Elsevier B.V. on behalf of Egyptian Society of Cardiology.
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Managing anticoagulation in pregnant women with mechani-
cal heart valve prosthesis (MHVP) is now mainly limited to
three alternatives: oral anticoagulants (OA) throughout preg-
nancy,1,2 OA substituted by heparin between the 6th and
12th gestational age, then resumed thereafter1–3; and heparin;
unfractionated or low molecular weight throughout preg-
nancy.1–3 The ﬁrst alternative was the choice of as much as
62–69.2% of the cases reported in 2 large systematic meta-
analysis studies that reviewed the subject over a 40 year
period4,5; and is the actual preferred regimen for one major
society, as long as the target international normalized ratio
(INR) is maintained with a limited dose of warfarin (LDW)
not exceeding 5 mg/day.2 This clinical trial was designed to
determine whether pregnant patients with mitral (±aortic)
MHVP could achieve the recommended high INR target
(2.5–3.5),1–3 with such a low dose.
2. Materials and methods
A prospective, randomized, parallel group, open label, single
center, clinical trial was designed to compare the proportions
of failure to reach a target INR (2.5–3.5) with either: LDW
(< 5 mg/day) or phenindione (< 100 mg/day) in pregnant
and non-pregnant patients with MHVP. Management com-
plied with the principles of the Helsinki Declaration. Follow-
ing local ethics committee approval and informed consent of
patients, the trial was registered with clinicaltrial.gov under
NCT01758640.
The study ﬂow diagram is presented in Fig. 1: 3000 patients
were screened at Ain Shams University Hospitals for their will-
ingness to conceiving (subpopulation A) or rejecting this idea
(subpopulation B). Equal study groups A (pregnant) and B
(non-pregnant), of 100 patients each, were created from the
respective populations with the following eligibility criteria:
(a) young females (18–40 years), (b) regular menstrual cycles
and no history of congenital malformation, repeated abortions
or still birth; (c) mitral (±aortic) MHVP, (d) NYHA class I-II
(e) achieving target INR (2.5–3.5) for the last 3 months with a
maximum warfarin dose of 5 mg/day (f) getting pregnant for
Group A patients. Patients refusing to sign the informed con-
sent, Group A patients reporting missed menstrual periods or
positive pregnancy tests >6th gestational weeks and Group B
who get pregnant; were all meant to be excluded. Using
blocked randomization with 3:1 allocation ratio, 100 patients
in each group were randomized to either receive: LDW or
phenindione; respectively. Concealed intervention allocation
was ensured with sealed envelopes and patient identiﬁcation
number.
Patients were enrolled between January 2009 and June
2012. In cases assigned to phenindione, it replaced warfarin
on the basis that 50 mg was equipotent to 3 mg warfarin.
Patients were followed-up till delivery or for 9 months (Group
B), with monthly cardiac examination, obstetrical examination
for Group A, check-ups for hepatorenal functions, complete
blood picture and echocardiography. Prothrombin time was
done on DADE BEHRING CA 1500 and INR was checked
out on randomization, 4 days following any dose adjustment
and then weekly. On the 2nd trimester (4th month in Group
B), 100 mg aspirin was added daily. Patients failing to achieveINR target for 2 successive controls were shifted to the other
OA and were ﬁnally excluded, if failure persisted. The INR
gap was bridged twice daily with LMWH 1 mg/kg. A fortnight
before delivery, pregnant patients were hospitalized and OA
was substituted with continuous infusion of UFH and a
planned delivery at 37th week per vagina or by Caesarian sec-
tion, as appropriate.
2.1. Primary outcome
Primary outcome was proportions of failure to achieve target
INR with either OA. Patients lost to follow-up were recorded
as last seen.
2.2. Secondary outcomes
Secondary outcomes were OA doses, INR, proportions of
adverse fetal outcomes (Group A), patient/maternal mortality
and anticoagulant-related complications. The latter being:
Grade I: questionable, minor thromboembolic or bleeding
events necessitating no treatment; Grade II: events requiring
outpatient treatment, without causing permanent damage;
and Grade III: events necessitating hospital treatment or caus-
ing permanent damage.6 Adverse fetal outcomes (spontaneous
abortions, embryopathy/congenital malformations, prematu-
rity and total fetal wastage) were expressed as proportions of
pregnancies and embryopathy/congenital malformations were
related to the number of live births.
2.3. Statistical analysis
Data were expressed as numbers (%) or mean ± SD, as
appropriate. In addition, primary outcome and its relative risk
were expressed as CI at 95%. Results were analyzed by Chi-
Square (or Fisher’s exact) test and unpaired Student’s (or
Mann–Whitney), when applied. All tests were done bilaterally.
P values 6 0.05 were considered statistically signiﬁcant. Sam-
ple size was calculated to detect a signiﬁcant difference in each
of the patients’ groups. Power calculations were based on the
assumption that phenindione may reduce the expected failure
rate to reach target INR with LDW from 30% to 5%. For a
3:1 ratio, the probability is 80% that the study can detect a dif-
ference at a two-sided 5% signiﬁcance level, if 75 patients and
25 patients were assigned to receive LDW and phenindione, in
each group. In respecting randomization, results were
primarily evaluated following the intention to treat approach.
A secondary per protocol analysis was planned for Group A,
to account for OA related adverse outcomes in the proportion
of patients who were expected to shift to the other OA and to
continue as such during the rest of pregnancy. The analysis
was performed with the statistical software package IBM
SPSS, version 21.3. Results
Between January 2010 and June 2012, 200 females (18–40;
30.1 ± 5.1 years) were enrolled in this study, 1–16 years
(5.38 ± 3) after mitral (+aortic; 23.5%) valve replacement
with Saint Jude (96; 48%), Carbomedics (74; 37%) or a Sorin
bileaﬂet valve (30; 15%). Pregnant patients were signiﬁcantly
Figure 1 Consort ﬂow diagram indicating patient screening and enrollment, treatment allocation, follow-up and analysis. n= number
of patients, (a) = 3 patients were lost to follow-up at 1, 3 and 6 months after randomization and were analyzed as last seen with respective
INR= 2.5, 2.4 and 3.
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ble (Table 1).
OA management included 7923 INR controls, with 5863
(74%) being within the therapeutic range, 1553 INR (19.6%)
below target and 507 (6.4%) were above target. Follow-up
was 100% complete for pregnant patients. Three group B
patients were lost to follow up and were analyzed as last seen.
All three patients had a mitral prosthesis, were among the 75
control cases assigned to LDW (4%) and were last seen 1, 3
and 6 months after randomization. Their last warfarin doses
and INRs were: 3, 5 and 4 mg and 2.5, 2.4 and 3, respectively.
3.1. Primary outcome
Group A: between the 5th and 12th weeks of gestation
(7.85 ± 1.87), 20 patients originally assigned to LDW
(26.7%; CI at 95% 16.7–36.7%) failed to achieve targetINR; compared to none of the 25 patients assigned to phenin-
dione (P= 0.003). Group B: 4 patients on LDW were
recorded as failures (5.3%; CI at 95%: 0.23–10.37%), com-
pared to none on phenindione (P= 0.5).
3.2. Secondary outcomes
In general, warfarin and phenindione doses varied between 1–
5 mg (3.6 ± 1.12; mg) and 25–100 mg (74.1 ± 24.3 mg);
respectively. The recorded INR varied between 1.5 and 9, with
a mean value of 2.94 ± 0.29; this being insigniﬁcantly different
between LDW patients (2.95 ± 0.29) and those on phenindi-
one (2.94 ± 0.29; P= 0.85), regardless of the patient’s group
(Table 2). In comparison to controls, pregnant patients
received signiﬁcantly higher doses of both OA (P< 0.0001)
and achieved signiﬁcantly lower INR levels (Table 2;
P< 0.0001); regardless to the assigned OA (Fig. 2;
Table 1 Patient demographics.
Variable Group A (n= 100) Total Group B (n= 100) Total P value c
Interventiona Interventiona
LDW
(n= 75)
Phenindione
(n= 25)
P valueb LDW
(n= 75)
Phenindione
(n= 25)
P valueb
1- Age (years) 28.3 ± 3.9 27.4 ± 3.7 0.3 28.1 ± 3.9 31.55 ± 5.5 33.2 ± 5.1 0.18 32.1 ± 5.5 <0.001
2- Mitral prosthesis:
Saint Jude valve 38 (50.7%) 15 (60%) 53 (53%) 32 (42.7%) 11 (44%) 43 (43%)
Carbomedics valve 26 (34.7%) 8 (32%) 34 (34%) 28 (37.3%) 12 (48%) 40 (40%)
Sorin bileaﬂet valve 11 (14.7%) 2 (8%) 0.6 13 (13%) 15 (20%) 2 (8%) 0.34 17 (17%) 0.357
Valve size (mm) 27.2 ± 1.7 27.24 ± 1.86 0.95 27.2 ± 1.7 27.1 ± 1.7 27.1 ± 1.9 0.94 27.1 ± 1.7 0.627
3- DVR 20 (26.7%) 4 (16%) 0.21 24 (24%) 17 (22.7%) 2 (8%) 0.14 19 (19%) 0.389
4- Aortic prosthesis:
Saint Jude valve 8 (40%) 3 (75%) 11 (11%) 4 (23.5%) 0 4 (4%)
Carbomedics valve 6 (30%) 1 (25%) 7 (7%) 6 (35.3%) 2 (100%) 8 (8%)
Sorin bileaﬂet valve 6 (30%) 0 0.35 6 (6%) 7 (41.2%) 0 0.2 7 (7%) 0.24
Valve size (mm) 20.9 ± 1.5 21.5 ± 1 0.46 21 ± 1.4 21 ± 1.4 20 ± 1.4 0.36 20.8 ± 1.4 0.812
5- Atrial ﬁbrillation 37 (49.3%) 10 (40%) 0.49 47 (47%) 43 (57.3%) 14 (56%) 1 57 (57%) 0.2
6-Implantation (years)d 5.1 ± 2.4 5.3 ± 2.8 0.72 5.1 ± 2.5 5.6 ± 3.8 5.8 ± 2.5 0.79 5.7 ± 3.5 0.22
Values are presented as numbers (%) or mean ± SD, as appropriate. Group A= pregnant patients, Group B = non-pregnant patients,
LDW= low dose warfarin, n= number of cases, DVR= double (aortic + mitral) valve replacement.
a LDW (65 mg/day) versus phenindione (6100 mg/day).
b Comparison of LDW to phenindione within the same group and comparison of Group A.
c Comparison of LDW to phenindione within the same group and Group B patients.
d Duration of prosthesis implantation in years.
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achieve target INR with LDW was 5 times that of controls
(95% CI: 1.8–13.9; P= 0.002). Considering the 3 Group B
patients lost to follow-up as failures reduces this relative risk
to 2.9 (1.3–6.3; P= 0.01).
We had no patient mortality but 21 anticoagulant related
complications (10.5%) that were neither related to the
patient’s group (Table 2) nor to the assigned OA: 15 among
LDW patients (10%) and 6 among patients on phenindione
(12%; P= 0.79). A stroke case was reported in a 40-year
old group B patient, 16 years after double valve replacement.
Her INR was 2.8 but her compliance to warfarin was ques-
tionable. We had 2 Grade III bleeding events in the form of
postpartum hemorrhage following vaginal delivery, with the
patients’ aPTT being more than twice that of control. Two
Grade II bleeding events were in the form of threatened
abortions at 14th and 16th gestational age. The respective
INRs were 3.4 and 5 and both cases were managed success-
fully. Eleven fetuses were lost (11%): 7 among patients
assigned to LDW (9.3%) and 4 among those assigned to
phenindione (16%; P= 0.46). Eighty-nine full-terms were
delivered per vagina (56 cases; 62.9%) or by Cesarean section
(32 cases; 37.1%) and showed no warfarin embryopathy or
other malformations. No statistically signiﬁcant differences
existed between mothers with adverse fetal outcomes and
other mothers regarding: age (27.36 ± 3.4 versus
28.16 ± 3.94 years; P= 0.2), atrial ﬁbrillation cases (6;
54.5% versus 41; 46.1%; P= 0.75), double valve replace-
ment (2; 18.2% versus 22; 24.7%; P= 1) or duration of
valve implantation (5.18 ± 2.5 versus 5.1 ± 2.5 years;
P= 0.93). On the other hand, the former received higher
doses of either warfarin (4.7 ± 0.4 versus 4.1 ± 0.9 mg;
P= 0.094) or phenindione (90 ± 22.4 versus 81.3 ±
24.2 mg; P= 0.45) and achieved signiﬁcantly lower INR(2.67 ± 0.11 versus 2.81 ± 0.21; P= 0.039), compared to
the latter.
3.4. Analysis per protocol for Group A patients
A total of 45 mothers were actually receiving phenindione dur-
ing the major period of pregnancy, compared to 55 patients
who continued the originally assigned warfarin therapy. As
shown in Table 3, there was no statistically signiﬁcant effect
of the type of OA being actually received on mean INR or
adverse maternal and fetal outcomes. Results were also com-
parable to those calculated by the intention to treat analysis
(Table 2).
4. Discussion
Pregnancy is a hypercoagulable state for decreasing natural
anticoagulants and ﬁbrinolytic activity and increasing most
of coagulation factors; including factors VII and X.7 As
prothrombin time responds to reduction in factors II, VII,
and X; the INR is expected to shorten during pregnancy,8
which has been shown in laboratory studies.9,10 Our study con-
ﬁrmed this ﬁnding: the INR recorded in pregnant patients
(2.81 ± 0.22) was signiﬁcantly lower than that of controls
(3.09 ± 0.29; P< 0.0001) and hence, more patients were
expected to drop below the set target during pregnancy, com-
pared to non-pregnant controls. Patients on phenindione
behaved likewise (Table 2, Fig. 2). De Santo and colleagues
recorded a statistically signiﬁcant decrease in INR after preg-
nancy in patients with MHVP (1.9 ± 0.3), compared to their
pre conception values (2.2 ± 0.5) however; and in comparison
to the actual report, their study included only 17 patients and
hence, it was not powered enough to detect a signiﬁcant drop
of INR till reaching lower below target.11
Table 2 Study outcomes.
Variable Group A (n= 100) Total Group B (n= 100) Total P valuec
Intervention (OA)a Intervention (OA)a
LDW (n= 75) Phenindione (n= 25) P valueb LDW (n= 75) Phenindione (n= 25) P valueb
Primary outcome:
Failure to reach INR target 20 (26.7%) 0 0.003 20 (20%) 4 (5.3%) 0 0.5 4 (4%) 0.001
Secondary outcomes:
1- OA dose (mg/day)d
(a) Warfarin – – – (n= 55) – – – (n= 71)
4.16 ± 0.88 3.22 ± 1.1 <0.0001
– – – (n= 45) – – – (n= 29)
(b) Phenindione 82.3 ± 23.9 60 ± 17.9 <0.0001
2- INR achieved 2.81 ± 0.22 2.76 ± 0.16 0.35 2.79 ± 0.21 3.0.9 ± 0.29 3.12 ± 0.28 0.67 3.1 ± 0.28 <0.0001
3- OA Complicationse:
Grade I: minor bleeding 3 (4%) 3 (12%) 6 (6%) 8 (10.7%) 2 (8%) 10 (10%)
Grade II: threatened abortion 1 (1.3%) 1 (4%) 2 (2%) – – –
Grade III: (a)- stroke 0 0 0 1 (1.3%) 0 1 (1%)
Post partum hemorrhage 2 (2.7%) 0 0.33 2 (2%) – – 0.78 0.32
4- Fetal outcomes:
(a) Full term 68 (90.7%) 21 (84%) 89 (89%)
(b) Spontaneous abortion 6 (8%) 3 (12%) 9 (9%)
(c) Still birth 1 (1.3%) 1 (4%) 0.58 2 (2%)
Values are presented as numbers (%) or mean ± SD; as appropriate. Group A = pregnant patients, group B = non-pregnant patients, OA= oral anticoagulant, LDW= low dose warfarin,
n= number of cases.
a LDW (65 mg/day) versus phenindione (6100 mg/day).
b Comparison of LDW to phenindione within the same group and comparison of Group A patients.
c Comparison of LDW to phenindione within the same group and comparison of Group B patients.
d 20 patients in Group A and 4 patient in Group B originally assigned to warfarin have failed to achieve INR target and were shifted to receive phenindione for the major part of the study.
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Figure 2 INR measures recorded during follow-up: course of pregnancy in Group A/9 months in Group B. Dots represent mean
monthly measures and bars represent ±95% CI. The reference line indicates the mean INR value (2.95) of all patients. Group
A= pregnant patients, Group B = non-pregnant patients. n= number of patients, P value = unpaired Student’s test comparing overall
mean value of INR records calculated for both patients’ groups, according to the originally assigned oral anticoagulant.
Table 3 Maternal and fetal outcomes: per protocol analysisa.
LDW
(n= 55)
Phenindione
(n= 45)
P value
1- Mean INR 2.31 ± 0.33 2.21 ± 0.26 0.1
2- Maternal complications:
(a) Threatened abortion 1 (1.8%) 1 (2.2%)
(b) Minor bleeding 3 (5.5%) 3 (6.7%) 0.96
3- Fetal outcomes:
(a) Full term babies 49 (89.1%) 40 (88.9%)
(b) Spontaneous abortion 5 (9.1%) 4 (8.9%)
c) Still birth 1 (1.8%) 1 (2.2%) 0.99
Values are presented as numbers (%) or mean ± SD, as appro-
priate. n= number of pregnancies, LDW= low dose warfarin
(65 mg/day).
a 20 pregnant patients failed to achieve target INR on LDW and
were shifted to phenindione therapy between 5th and 12th weeks of
gestation (7.85 ± 1.87) and until delivery.
120 A. Hassouna et al.As much as 26.7% of our pregnant patients on LDW failed
to achieve the high INR target (2.5–3.5) recommended for a
mitral prosthesis,1–3 with a relative risk of 5 times that of
controls. Those failure rates were never analyzed before, but
sometimes reported alongside data.11–18 For the majority of
the studies being retrospective13–15,17,18 and, in many times,
presenting incomplete14,17 or imprecise data16,18; failure toachieve target INR during pregnancy widely varied between
0%16,18 and 50%.14 One complete retrospective study calcu-
lated a 40% failure rate in 58 pregnancies.13 In concordance
with our results, 2 prospective studies from the same institu-
tion reported much smaller rates (15–17.2%) in non-pregnant
females.11,12
We are ﬁrst to note that pregnant patients did ‘‘consume’’
more (OA) than their controls, regardless of the type of OA
(Table 2; P< 0.001). De Santo and colleagues did not record
any increase in the dose of warfarin after pregnancy, despite
the signiﬁcant decrease in INR.11 One retrospective study
has even noted a decrease in both: warfarin dose and INR dur-
ing pregnancy.18 From our point of view, if the physician’s
primary concern is to maintain target INR of his pregnant
patient and respecting the dosage limits comes in second;
warfarin doses are expected to increase during pregnancy, in
consequence to the signiﬁcant decrease in INR values. Like-
wise, signiﬁcantly higher doses of phenindione were necessary
for pregnant patients (Table 2) to achieve signiﬁcantly lower
INR values (Fig. 2), when compared to controls.
The low rate of fetal loss, absence of fetal embryopathy, pros-
thetic valve thrombosis or maternal mortality were also
reported by all prospective studies adopting LDW11,12,16; sup-
porting the general idea that warfarin induced complications
may be dose related.1–3,11–13,17,19 Although the INR of mothers
with adverse fetal outcomes was signiﬁcantly lower than that
recorded for those enjoying healthy babies, it is well known that
Limited dose warfarin throughout pregnancy 121the INR of the fetus, with immature liver enzyme systems, is
expected to be higher than that of the mother.20 In one study,
maternal prothrombin ratio of 19 mothers was 1.23 ± 0.38,
while the mean INR recorded for 6 of their neonates was
2.9.12 In consequence, we ﬁnd it more appropriate to correlate
fetal adverse outcomes with both maternal and neonatal INR.
Unfortunately, the latter was not recorded in the actual study.
The serious side effects that have been related to phenindi-
one and limited its use worldwide were all presented as case
reports,21,22 without a single prospective or large retrospective
study. We did not encounter any of those complications on a
remarkable scale, whether in non-pregnant23 or in pregnant
patients.24 On the other hand, facing the well-documented
teratogenic risk of warfarin; numerous reports have
described,25,26 or even recommended,25 the safe use of phenin-
dione during pregnancy. To the best of our knowledge, a typ-
ical warfarin like embryopathy was described in a single case
on phenindione with the patient also receiving diphenylhydan-
toin and primidone; drugs that have been associated with dig-
ital hypoplasia and facial abnormalities.27 We have previously
reported prospective pregnancy outcomes in 31 cases receiving
a maximum daily dose of 100 mg phenindione throughout
pregnancy, with 2 fetal losses (6.4%) and without a single fetal
embryopathy.24
In our experience, as well as that of others,28 the anticoag-
ulation effect of 50 mg of phenindione was nearly equipotent
to 3 mg of warfarin, in most patients. Consequently, the
100 mg/day ‘‘safe dose’’ of phenindione can provide an extra
20% ‘‘safe anticoagulation effect’’, in comparison to the
5 mg/day safe dose of warfarin; making phenindione (Dind-
evan) an attractive alternative OA in fertile females. How-
ever, this study was not powered enough to detect signiﬁcant
differences between pregnancy outcomes of both OA and lar-
ger prospective controlled studies are still needed to test the
safety of phenindione on both mother and fetus.
5. Conclusion
This study showed that a signiﬁcant portion of pregnant
patients with a mitral (±aortic) MHVP would fail to achieve
the required target INR with LDW. Failure in non-pregnant
controls was signiﬁcantly smaller. Phenindione offered an
effective alternative; which safety needs to be further
investigated.
6. Study imitations and expectations
Our study was primarily concerned about those patients who
will eventually fail to maintain their INR target on 2 successive
assessments and are then obliged to change their OA regimen.
It would have been beneﬁcial to record the percentage of time
the remaining patients have continued to achieve their INR
target; with its probable effect on pregnancy outcomes.
Although phenindione is our anticoagulant of choice in fertile
females, its limited use worldwide was behind the unbalanced
3:1 design, posed by the ethics committee as a protective
restriction. We were underpowered to detect differences in
adverse fetal outcomes between both OA and we did not
record fetal INR for correlation with those outcomes. The
limited resources restrained us from comparing LDW to low
molecular weight heparin.Funding
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